Cargando…

Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody

In this study, the peptide sized 21 kDa covering P-gp transmembrane region was first prepared for generating a novel mouse monoclonal antibody Fab fragment with biological activity against multiple drug resistance protein P-gp(21) by phage display technology. Phage-displayed antibody library prepare...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuemei, Xiao, Gary Guishan, Gao, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856173/
https://www.ncbi.nlm.nih.gov/pubmed/24348182
http://dx.doi.org/10.1155/2013/716289
_version_ 1782295036050800640
author Zhang, Xuemei
Xiao, Gary Guishan
Gao, Ying
author_facet Zhang, Xuemei
Xiao, Gary Guishan
Gao, Ying
author_sort Zhang, Xuemei
collection PubMed
description In this study, the peptide sized 21 kDa covering P-gp transmembrane region was first prepared for generating a novel mouse monoclonal antibody Fab fragment with biological activity against multiple drug resistance protein P-gp(21) by phage display technology. Phage-displayed antibody library prepared from mice spleen tissues was selected against the recombinant protein P-gp(21) with five rounds of panning. A number of clones expressing Fab bound to P-gp(21), showing neutralized activity in vitro, were isolated and screened by enzyme-linked immunosorbent assay based on its recognition properties to P-gp(21) and human colorectal cancer tissue homogenate, resulting in identification of an optimal recombinant Fab clone (Number 29). Further characterization by recloning number 29 into an expression vector showed significant induction of the Fab antibody in the clone number 29 by Isopropyl β-D-1-thiogalactopyranoside (IPTG). After purified by HiTrap Protein L, the specificity of the Fab antibody to P-gp(21) was also confirmed. Not only was the targeted region of this monoclonal Fab antibody identified as a 16-peptide epitope (ALKDKKELEGSGKIAT) comprising residues 883–898 within the transmembrane (TM) domain of human P-gp, but also the binding ability with it was verified. The clinical implication of our results for development of personalized therapy of colorectal cancer will be further studied.
format Online
Article
Text
id pubmed-3856173
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38561732013-12-17 Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody Zhang, Xuemei Xiao, Gary Guishan Gao, Ying ScientificWorldJournal Research Article In this study, the peptide sized 21 kDa covering P-gp transmembrane region was first prepared for generating a novel mouse monoclonal antibody Fab fragment with biological activity against multiple drug resistance protein P-gp(21) by phage display technology. Phage-displayed antibody library prepared from mice spleen tissues was selected against the recombinant protein P-gp(21) with five rounds of panning. A number of clones expressing Fab bound to P-gp(21), showing neutralized activity in vitro, were isolated and screened by enzyme-linked immunosorbent assay based on its recognition properties to P-gp(21) and human colorectal cancer tissue homogenate, resulting in identification of an optimal recombinant Fab clone (Number 29). Further characterization by recloning number 29 into an expression vector showed significant induction of the Fab antibody in the clone number 29 by Isopropyl β-D-1-thiogalactopyranoside (IPTG). After purified by HiTrap Protein L, the specificity of the Fab antibody to P-gp(21) was also confirmed. Not only was the targeted region of this monoclonal Fab antibody identified as a 16-peptide epitope (ALKDKKELEGSGKIAT) comprising residues 883–898 within the transmembrane (TM) domain of human P-gp, but also the binding ability with it was verified. The clinical implication of our results for development of personalized therapy of colorectal cancer will be further studied. Hindawi Publishing Corporation 2013-11-07 /pmc/articles/PMC3856173/ /pubmed/24348182 http://dx.doi.org/10.1155/2013/716289 Text en Copyright © 2013 Xuemei Zhang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhang, Xuemei
Xiao, Gary Guishan
Gao, Ying
Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title_full Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title_fullStr Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title_full_unstemmed Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title_short Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
title_sort characterization of human colorectal cancer mdr1/p-gp fab antibody
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856173/
https://www.ncbi.nlm.nih.gov/pubmed/24348182
http://dx.doi.org/10.1155/2013/716289
work_keys_str_mv AT zhangxuemei characterizationofhumancolorectalcancermdr1pgpfabantibody
AT xiaogaryguishan characterizationofhumancolorectalcancermdr1pgpfabantibody
AT gaoying characterizationofhumancolorectalcancermdr1pgpfabantibody